Oragenics Obtains U.S. Patent for IVIAT

October 17, 2011

Oragenics, Inc., Tampa, FL, has been issued patent No. 8,034,571 from the U.S. Patent and Trademark office for In Vivo Induced Antigen Technology (IVIAT). This platform technology is a novel approach for studying microbial pathogenesis that identifies genes of a pathogenic organism, which are differentially expressed during an actual human infection. IVIAT can be applied to all pathogenic bacteria, yeasts and parasites to rapidly identify proteins that are expressed when a pathogen infects a human. Such proteins are excellent targets for medical diagnostics and therapeutic strategies.
  • Energy Trends: The Market Charges On

    Energy Trends: The Market Charges On

    Sean Moloughney, Editor||January 3, 2017
    Brands appeal to a broad audience with natural ingredients that provide sustained benefits.

  • Nutritional Minerals: Tried & True

    Nutritional Minerals: Tried & True

    Lisa Olivo, Associate Editor||January 3, 2017
    Among the most elementary ingredients in the nutraceuticals space, minerals continue to benefit public health.

  • Healthy Snack Trends to Chew On

    Healthy Snack Trends to Chew On

    Amanda Baltazar, Contributing Writer||January 3, 2017
    Consumers are seeking more positive attributes and fewer ingredients from their snacks and nutrition bars.